Case Study
Launch of a drug discovery consortium to address the unmet therapeutic needs of people living with mental health conditions
The Psychiatry Consortium is a £4 million international collaboration between seven global pharmaceutical companies and two leading medical research charities, convened and managed by Medicines Discovery Catapult, to support high-value drug discovery projects that address the unmet therapeutic needs of people living with mental health conditions, including psychiatric symptoms associated with dementia.